Willow Biosciences Inc (ATLE) AI Stock Analysis

• Market Cap: C$59.88M
• Dividend Yield: N/A
• Average Volume (3M): 26.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 190.43%
• EPS Growth: 71.05%
• Country: CA
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 352,222,660
• 10 Day Avg. Volume: 47,704
• 30 Day Avg. Volume: 26,236
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by significant financial challenges, including negative equity and cash flow issues, despite strong revenue growth. Technical analysis provides a neutral outlook, while valuation remains a concern due to negative earnings.

Willow Biosciences Inc Business Overview & Revenue Model

Company Description

Willow Biosciences Inc. (ATLE) is a biotechnology company focused on developing and commercializing innovative solutions for the production of bioactive compounds through synthetic biology. The company operates primarily in the biotechnology sector, specializing in the development of proprietary production processes for cannabinoids and other high-value compounds. Willow's core products and services include advanced biosynthesis techniques that enable the sustainable and cost-effective production of compounds for use in the pharmaceutical, nutraceutical, and consumer goods industries.

How the Company Makes Money

Willow Biosciences Inc. generates revenue through several key streams. Primarily, the company monetizes its proprietary biosynthesis technology by entering into partnerships and licensing agreements with other companies in the pharmaceutical and nutraceutical sectors. These partnerships often involve co-development agreements where Willow provides its expertise in synthetic biology to help partners create and manufacture bioactive compounds. Additionally, Willow may sell its proprietary products directly to manufacturers looking for high-quality cannabinoids or other bioactive ingredients. The company may also earn revenue through research and development funding from collaborations with academic institutions or larger corporations seeking to innovate in the field of biosynthesis. Factors contributing to its earnings include the increasing demand for sustainable and efficient production methods in the biotech industry, as well as the growing acceptance and legalization of cannabinoids in various markets.

Willow Biosciences Inc Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Willow Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ATLE, the sentiment is Negative. The current price of 0.17 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.16, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.57 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ATLE.

Willow Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATLE	45 Neutral	C$59.88M	-1.69	-24.60%	―	190.43%	71.05%
OVAT	39 Underperform	C$1.41M	―	―	―	-36.47%	34.50%
CVGR	20 Underperform	$3.20M	-5.04	―	―	―	77.83%

Willow Biosciences Inc Corporate Events

Atlas Energy Reports Strong Q2 2025 Results and Strategic Recapitalization

Atlas Energy Corp. has announced its second-quarter financial results for 2025, highlighting a $30 million recapitalization that underscores strong investor confidence in its strategic direction. The company’s shares have been voluntarily delisted from the OTCQB but continue to trade on the TSX Venture Exchange and the OTC Pink platform, reflecting its focus on executing a targeted acquisition strategy in undercapitalized markets.

The most recent analyst rating on (TSE:ATLE) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Willow Biosciences Inc stock, see the TSE:ATLE Stock Forecast page.